- Home
- TLSI vs GRX Comparison
TLSI vs GRX Comparison
Compare TLSI & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSI | GRX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.2M | 140.5M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TLSI | GRX |
|---|---|---|
| Price | $4.43 | $9.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 231.9K | 21.7K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,151,000.00 | N/A |
| Revenue This Year | $35.45 | N/A |
| Revenue Next Year | $37.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.41 | N/A |
| 52 Week Low | $2.20 | $8.80 |
| 52 Week High | $7.95 | $10.20 |
Technical Indicators
Market Signals| Indicator | TLSI | GRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 42.97 |
| Support Level | $4.28 | $9.49 |
| Resistance Level | $4.47 | $9.73 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 2.32 | 26.74 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.